Micromanaging Glucose Tolerance and Diabetes

Negar Saliani1, Soheila Montazeraheb2, Shideh Montasser Kouhsari1*

1Department of Cellular and Molecular Biology, School of Biology, College of Sciences, University of Tehran, Tehran, Iran.
2Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract
MicroRNAs (miRNAs) are endogenous non-coding RNAs that have significant roles in biological processes such as glucose homeostasis. MiRNAs fine-tune target genes expression via sequence-specific binding of their seed sequence to the untranslated region of miRNAs and degrade target miRNAs. MicroRNAs in islet β-cells regulate β-cell differentiation, proliferation, insulin transcription and glucose-stimulated insulin secretion. Furthermore, miRNAs play key roles in the regulation of glucose and lipid metabolisms and modify insulin sensitivity by controlling metabolic functions in main target organs of insulin such as skeletal muscle, liver and adipose tissue. Moreover, since circulating miRNAs are detectable and stable in serum, levels of certain miRNAs seem to be novel biomarkers for prediction of diabetes mellitus.

In this article, due to the prominent impact of miRNAs on diabetes, we overviewed the microRNAs regulatory functions in organs related to insulin resistance and diabetes and shed light on their potential as diagnostic and therapeutic markers for diabetes.

Introduction
MicroRNAs (miRNAs) are one of epigenetic mechanisms that modulate different biological processes via silencing in some cases activating gene expression.1,2 miRNAs are 18–25 nucleotides long and these non-coding RNA molecules are involved in post-transcriptional regulation of large number of genes in various organisms (up to 30% genes). This class of RNAs has highly conserved structure. The first miRNA, lin-4, was discovered in nematode Caenorhabditis elegans, less than 40 years ago.3,4 After then, different groups have found miRNAs in some plants and metazoa.3,6

MiRNAs degrade target mRNA or inhibit protein translation in order to inactivate their target genes. This function occurs by binding the “seed sequence” 2–8 nucleotides at 5’ end of miRNA to “untranslated sites” the 3 ’ UTR of the target mRNA. However 5 ’ UTR, promoter elements or coding sequences of target genes are interaction regions for seed sequences.6 Depending on the binding quality, the mechanism of regulation is different. In the perfect binding, RNA-induced silencing complex (RISC) is active and fragmentizes the target mRNA, but in weak binding situation miRNA interferes the ribosome assembly or leads to early detachment of ribosome from mRNA. Also, exonucleolytic digestion can happen via deadenylation and decapping of target mRNA.7,8

Several miRNAs can recognize a distinct gene and interact with it. On the other hand, a single miRNA can bind lots of genes. There is not a same annotation criteria to analyze miRNAs, so their number is not exactly clear. Actually, about 2500 well known miRNAs have been found in the human genome.9 Each miRNA is assigned a name and registered to miRNAs catalog which is available in miRBase database (www.mirbase.org; v21 June 2014).10

MicroRNA biogenesis
Three major enzymes are involved in miRNA biogenesis, RNA polymerase II, ribonuclease III enzymes (RNase -III), Drosha and Dicer, which act in nucleus and cytoplasm respectively. At the first step, RNA polymerase II transcribes miRNA and produces primary-miRNA (pri-miRNA) which contains a stem-loop structure where the dsRNA-binding protein named DGCR8 in humans, and Pasha in Drosophila melanogaster and Caenorhabditis elegans and Drosha (microprocessor complex), cleave it into miRNAs (pre-miRNA).9,11,12 This cleavage is done in both strands of the stem near the base of the primary stem-loop. Some regulatory proteins such as SMAD (small mothers against decapentaplegic) proteins, the signal transducers of TGFB/ BMP (transforming growth factor beta/ bone morphogenetic protein) accompany RNase III endonuclease to regulate its function.13

At the second step, cytoplasmic processing begins by RNase III endonuclease, Dicer1. XPO5 is responsible for transfer of pre-miRNAs from nucleus to cytoplasm. Cofactor of XPO5 is Ran-guanosine triphosphate–dependent nucleo/cytoplasmic cargo.14 Dicer1 in presence of dsRNA binding protein, TARBP2 [TAR (HIV-1) RNA binding protein 2], produces a small
double stranded miRNA by digesting the loop side of the pre-miRNA hairpin.\textsuperscript{15} MiRNA maturation is accomplished by helicases which unwind this truncated double strand miRNA to produce a single strand. The single strand RNA is active and enters Argonaute (AGO) to destroy target miRNAs. Generally, “guide” strand or “+ strand” is functional and “passenger” strand or strand or “- strand” is destroyed.\textsuperscript{16} A large number of mature miRNAs act in cytoplasm after maturation but some of them have capacity to control the gene expression in other cells. They can release into biological fluid or cell culture media.\textsuperscript{17}

**MicroRNAs acting on pancreatic β-cells differentiation and functions**

The differentiation of insulin-producing β-cells, the highly proficient cells, is orchestrated with several signaling pathways and molecular mechanisms from fetal period until weaning. The ample evidence declares that miRNAs play pivotal roles in β-cell differentiation and functions. Importantly, generation of Dicer-null β-cells resulted in a complete loss of insulin-secreting cells.\textsuperscript{18,19} β-cell specific deletion of Dicer1 using the rat insulin promoter 2 (RIP)-Cre transgene led to impaired pancreas development, declined β-cell mass and insulin secretion.\textsuperscript{20} In line with this evidence, recent study on βDicer-null mice indicated that miRNA loss primarily afflicts β-cell secretory function prior to any decrease in insulin content or β-cell mass.\textsuperscript{21} Investigations for finding the exhaustive list of miRNAs in β-cell differentiation are presently in the limelight. In 2004, the pioneering study demonstrated that miR-375 is highly expressed in pancreatic β-cells and contributes to the β-cell differentiation, pancreas development, insulin biogenesis, insulin secretion and generates the β-cell identity.\textsuperscript{22} Over-expression of miR-375 induces human embryonic stem cells differentiation into islet β-cells in culture in a stepwise process and its expression pattern resembles that of the human fetal pancreas.\textsuperscript{23} Furthermore, up-regulation of miR-375 following treatment with anti-miR-9 in human bone marrow mesenchymal stem cells induces differentiation into mature islet like clusters and improves insulin secretion in a glucose-regulated manner by virtue of controlling the levels of key transcription factors involved in pancreatic β-cells maturation such as SOX-17 and HNF-3 beta/FoxA2.\textsuperscript{24} Nathan et al. showed that expansion of human islet β-cells from adult human pancreatic islets is usually skewed due to the modifications in miRNAs expression. They demonstrated that over-expression of miR-375 in β-cell-derived cells redifferentiated them to cells with more β-cell functional phenotype.\textsuperscript{25} Also, it was found that miR-375 and miR-184 form a network with AGO2 to regulate β-cell expansion.\textsuperscript{26} Emerging data suggests that miR-124a, plays a prominent role in β-cell differentiation and insulin secretion. Expression of miR-124a elevates during mouse embryonic pancreas development. FoxA2, a transcription factor essential for β-cell differentiation and insulin secretion, is a target of miR-124a.\textsuperscript{27} Consistent with this finding, Neurog3, a major β-cell transcription factor which regulates pancreas development and differentiation, was identified as a specific target of miR-124a.\textsuperscript{28} Glucose-stimulated insulin secretion (GSIS) is a critical process which controls the metabolic homeostasis. Several miRNAs are directly involved in GSIS.\textsuperscript{29} MiR-375 inhibits GSIS at the late stages of exocytosis in pancreatic β-cells by targeting myotrophin.\textsuperscript{32} cAMP as a second messenger, increases insulin secretion in the presence of glucose and activates PKA, which subsequently phosphorylates and activates downstream targets in order to enhance GSIS.\textsuperscript{30,31} It has been shown that reduced miR-375 expression enhances GSIS via cAMP/PKA-dependent or PKA-independent pathway.\textsuperscript{32,33} 

Mir-9 negatively regulates GSIS by targeting Sirt1 and OneCt2. The enzyme Sirt1, deacetylates histones and transcription factors in an NAD-dependent manner and is important in the regulation of insulin secretion.\textsuperscript{34} OneCt2, a transcription factor, regulates the expression of granuphilin which negatively modifies the exocytosis of insulin-containing granules.\textsuperscript{35} In MIN6 and INS-1 cell lines, mir-124 regulates potassium channel subunits, Kir6.2 and SUR1, by targeting FoxA2 and leads to altering the Ca\textsuperscript{2+}-sensitivity of β-cell and insulin secretion.\textsuperscript{27} Although Rab27A is a direct target of mir-124a, some other exocytosis-related proteins such as SNAP25, Rab3A, Synapsin-1A, and Noc2 are regulated by mir-124a indirectly.\textsuperscript{36} Recent study revealed that miRNA-463-3p/ABCG4 (ATP-binding cassette sub-family G member 4) axis plays an important role in GSIS and inhibits this process. In type 2 diabetic patients, miRNA-463-3p is up-regulated and ABCG4 is down-regulated in pancreatic β-cells.\textsuperscript{37} over-expression of miR-96 diminishes the exocytosis through increase in granuphilin expression and decrease in Noc2 level.\textsuperscript{36} Granuphilin negatively modifies exocytosis\textsuperscript{38} whereas Noc2 binds to Rab3 and ameliorates insulin secretion.\textsuperscript{38} Over-expression of miR-21 and miR-34a decreases insulin secretion by targeting VAMP2 and Rab3a.\textsuperscript{39,40} Additionally, miR-29a targets Syntaxin-1A and impairs the insulin secretion in glucose-dependent manner.\textsuperscript{41} Accordingly, miRNAs can regulate GSIS and contribute to the hyperglycemia seen in diabetes (Table 1). Prolonged glucose stimulation activates β-cell specific insulin transcription factors such as MafA, PDX1, NeuroD and particularly miRNAs.\textsuperscript{42} In the hyperglycemic diabetic mouse model B6 ob/ob, augmented expression of miR-204, reduced insulin synthesis by targeting and down-regulating MafA.\textsuperscript{43} Over-expression of miR-9 in vivo decreased insulin expression via targeting OneCt2 transcription factor.\textsuperscript{35} MiR-30d has glucose-dependent expression and its up-regulation increases insulin transcription through indirect targeting of MafA.\textsuperscript{44,45} Further, continuous glucose exposure in INS-1E cells down-regulates the level of miR-375. MiR-375 directly
targets PDK1 and affects the phosphorylation of PKB and GSK3, downstream kinases in the PI3-kinase signaling cascade, subsequently, inhibits glucose-induced β-cell proliferation and insulin transcription\(^6\) (Table 1).

The β-cells in the developing pancreas are extremely proliferative. By producing insulin via the progenitor cells, the proliferation depletes profoundly.\(^{47}\) In human, proliferation of adult pancreatic β-cells is low to undeterminable under steady-state conditions.\(^{48,49}\) Significantly, genetic studies reveal that miR-375 is one of the rare miRNAs, which its knockdown is implicated in defects in islet architecture and function of insulin producing cells.\(^{50}\) Genetic inactivation of miR-375 in zebrafish causes decrease in beta cell mass and consequently depletes insulin production and triggers the onset of diabetes.\(^{51}\) Studies on a miR-375 KO mouse model displayed genetic inactivation of miR-375 reduced β-cell mass but increased α-cell number, improved hyperglycemic state and GSIS.\(^{52}\) Indeed, appropriate level of miR-375 is also critical for expanding fetal β-cell mass and preventing abnormal glucose homeostasis. In human, miR-7 is highly expressed in both the developing and adult pancreas.\(^{53-55}\) Transfecting human islets beta cells with anti-miR-7a demonstrated a 30-fold increase in proliferation, so it underscores the potential of miR-7 as a negative regulator of proliferation.\(^{56}\) β-cell mass in the adult human increases in response to insulin resistance (IR) during obesity and pregnancy.\(^{48,57}\) The loss of β-cell mass is associated with both type 1 (T1D) and type 2 diabetes (T2D). The hunt for finding novel mechanisms to propel β-cell to develop and regenerate can hold promise in increasing the number of functional β-cells in patients with diabetes. Neurog3, a key regulator of β-cell differentiation, is not expressed during the regenerative phase.\(^{58}\) Profiling 283 miRNA expression levels of developing and regenerating pancreas showed that miRNAs targeting Neurog3 (miR-15a, miR-15b, miR-16 and miR-195) have the most expression during pancreas regeneration. It is plausible that, microRNAs regulate Neurog3 expression during regeneration in the adult mouse pancreas. MiR-200 family is the principal regulator of β-cell apoptosis in T2D. In other words, miR-200 family is over-expressed in islets of diabetic mice and induces β-cell apoptosis and T2D development through targeting essential β-cell chaperone Dnajc3 (p58IPK) and the caspase inhibitor Xiap. The loss of miR-200 function protects β-cells against both oxidative and DNA damage stress and represses expression of pro-apoptotic genes.\(^{59}\) During the development of diabetes, up-regulation of miR-21 in β-cells induces apoptosis by degradation of BCL2 mRNA and inhibition of BCL2 mRNA translation\(^{60}\) (Table 2).

### Table 1. miRNAs acting on GSIS and insulin transcription

| miRNAs | functional effect       | Targets                        | Tissue/cell  | References |
|--------|-------------------------|--------------------------------|--------------|------------|
| miR-30d | Insulin transcription   | Mafα                           | MIN6         | 44,45      |
| miR-204 | Insulin secretion       | Mafα                           | mouse ob/ob islets | 22,43      |
| miR-375 | Insulin transcription, insulin secretion | PDK1, myotrophin | Mouse islets/INS-1E | 22         |
| miR-9  | Insulin secretion       | Onecut2, Granulophilin         | INS-1E       | 35         |
| miR-21 | Insulin secretion       | VAMP2, Rab3a                   | MIN6         | 39         |
| miR-29a | Insulin secretion       | Syntaxin-1A                    | INS-1E       | 41,98      |
| miR-34a | Insulin secretion       | VAMP2, Rab3a                   | MIN6         | 39         |
| miR-96 | Insulin secretion       | Noc2, Granulophilin            | MIN6         | 36         |
| miR-124a | Insulin secretion     | Foxa2, Rab27a, Noc2, SNAP25    | MIN6 and INS-1 832/13 | 27,36 |
| miR-463 | Insulin secretion       | ABCG4                          | Human        | 37         |

### Table 2. miRNAs regulating β-cell development

| miRNAs | functional effect       | Targets   | Tissue/cell  | References |
|--------|-------------------------|-----------|--------------|------------|
| miR-15a, miR-15b, miR-16, miR-195 | Pancreas development, β-cells fate and regeneration | Neurog3 | mouse embryo/MIN6 | 28  |
| miR-7a  | Human β-cell proliferation | p70S6 K, elf4E, Mapkap1, Mnk1 and Mnk2 | mouse islets | 53,56,99 |
| miR-375 | α- and β-cell expansion | Cav1, Id3, Smarca2, Aifm1, Rasd1, Rgs16, Eef1e1, C1qbp, HuD, Cadm1 | KO mouse islets | 52  |
| miR-124a | Pancreas development and β-cells functional | Foxa2, Neurog3 | MIN6 , mouse islets | 27,28 |

**MicroRNAs acting on skeletal muscle insulin sensitivity**

Muscle tissue is the largest consumer of glucose in the human body. Impaired insulin-stimulated glucose uptake and glucose utilization are the characteristics of insulin resistance in skeletal muscles.\(^{60}\) Also, insulin resistance and T2D can be attributed to diminished mitochondrial function in skeletal muscle.\(^{61}\)
In striated muscle, some miRNAs such as miR-1, miR-133a/b-3p, miR-206-3p, miR-208a/b-3p and miR-499-5p are the tissue-specific miRNAs with expression levels of at least 20-fold higher in comparison to other tissues. Additionally, theses miRNAs accounts for 25% of total miRNAs express in skeletal muscle and are termed "myomiRs". Most myomiR family members are expressed in both cardiac and skeletal muscle with the exception of miR-208a-3p which is cardiac-specific and miR-206, which is skeletal muscle-specific. MiR-486 has expression in other tissues and considered "muscle-enriched" rather than "muscle-specific". 

"mitomiR" is a term given to the miRNAs identified inside mitochondria. Of relevant importance is that miRNAs are implicated in regulation of mitochondrial biogenesis, energy metabolism, and electron transport chain subunits.

Intriguingly, epigenetics regulates gene expression in response to extracellular stimuli or pathological states. Exercise is known to have beneficial effects on T2D and IR. Previous studies reveled that exercise leads to epigenetic modifications such as DNA methylation. It has been well-characterized that response to exercise in skeletal muscle is largely mediated by miRNAs which post-transcriptionally regulate gene expression. Markedly, regarding insulin sensitivity, exercise alters skeletal muscle genes and microRNAs expressions such as miR-378s(Table 3). Acute exercise resulted in increased levels of miR-1, miR-107, miR-181s and miR-133a and diminished miR-23 levels which it can up-regulated peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Furthermore, through analysis of epigenetic changes in skeletal muscle of T2D patients in response to both types of exercise revealed a metabolic reprogramming.

| miRNAs        | Cell types          | functional effect                                           | References |
|---------------|---------------------|------------------------------------------------------------|------------|
| Myomirs: miR-1, miR-133, miR-206 | Skeletal muscle | Myogenesis                                                  | 100,101 |
| miR-1, miR-107, miR-133, miR-181 | Skeletal muscle | -                                                         | 68,69 |
| miR-23a       | Skeletal muscle     | Associated with PGC-1α upregulation                        | 70         |
| miR-29a       | Skeletal muscle     | Impairs insulin-stimulated glucose uptake, IRS-1           | 98,102 |
| miR-206       | Skeletal muscle     | Fiber type transition                                      | 103        |
| miR-106       | Skeletal muscle     | -                                                         | 104,105 |
| miR-24        | Skeletal muscle     | -                                                         | 105        |
| miR-27        | Adipose tissue      | Adipocyte differentiation                                  | 106        |
| miR-29a       | Adipose tissue      | Impairs insulin-stimulated glucose uptake                  | 98         |
| miR-133       | Adipose tissue      | Adipocyte differentiation                                  | 78         |
| miR-143       | Adipose tissue      | Adipocyte differentiation, insulin resistance              | 79,107 |
| miR-93        | Adipose tissue      | Insulin resistance                                         | 77         |
| miR-126       | Adipose tissue      | -                                                         | 105        |
| miR-221       | Adipose tissue      | Insulin resistance                                         | 80         |
| miR-320       | Adipose tissue      | Insulin resistance                                         | 75         |
| miR-193b, miR 365, miR-196a, miR-155, miR-133a/b, miR 455 and miR-30 | Adipose tissue | Browning of white fat                                       | 83         |
| miR-103       | Adipose tissue/liver| Insulin resistance                                         | 78         |
| miR-107       | Adipose tissue/liver| Insulin resistance                                         | 78         |
| miR-33        | Liver               | Controls HDL biogenesis                                    | 87,88     |
| miR-122       | Liver               | Controls VLDL secretion                                    | 85,108    |
| miR-181a      | Liver               | Improves insulin resistance                                | 90         |
| miR-802       | Liver               | Insulin resistance                                         | 109        |

**Table 3. miRNAs in skeletal muscle, adipose tissue and liver contribute to diabetes**

---

**MicroRNAs acting on adipose tissue insulin sensitivity**

Adipose tissue is a highly active metabolic endocrine organ and one of the important targets of insulin action. Excess adipose tissue contributes to obesity related metabolic diseases. Multiple lines of evidence underscore the importance of miRNAs in adipogenesis and obesity. Over-expressed miR-223 in adipose tissues of IR patients reduced GLUT4 protein content and subsequently impaired glucose uptake in these tissues.
MicroRNAs acting on liver insulin sensitivity

Hepatic insulin resistance disturbs glucose and lipid metabolism and also is a contributing factor in the pathogenesis of T2D and metabolic syndrome. MiR-122 is abundantly expressed in liver and constitutes up to 70% of all liver microRNAs. Inhibition of this microRNA is implicated in decreased hepatic steatosis, plasma cholesterol\(^\text{84}\) and also results in decreased circulating lipoprotein levels through reduction of very low density lipoprotein (VLDL) secretion.\(^\text{85}\) Moreover, miR-223 controls cholesterol biosynthesis and high density lipoprotein (HDL) uptake in the liver.\(^\text{96}\) MiR-33b and miR-33a via SREBP1 and 2, respectively\(^\text{87,88}\) and miR-29 through regulation of Ahr and Sirt1 impact on cholesterol and lipoprotein metabolism.\(^\text{89}\) Additionally, MiR-181a improves hepatocyte insulin sensitivity via down-regulation of Sirt1.\(^\text{90}\) Liver insulin resistance results in decreased miR-338-3p expression. Several other miRNAs such as miR-143, miR-181a, miR-103, miR-107, miR-802 has been shown to improve insulin sensitivity\(^\text{91}\) (Table 3).

MicroRNAs as circulating biomarkers

Large set of miRNAs besides their intracellular function are found in bio fluids, such as blood, urine and saliva.\(^\text{91}\) Variations in the miRNA patterns of bio fluids are emerging as promising biomarkers of several pathological conditions including diabetes.\(^\text{92-96}\) One of the first studies to evaluate the circulating miRNAs profile changes associated with T2DM identified most significantly changed miRNA: miR-15a, miR-126, miR-223, miR-320, and miR-28-3p were able to distinguish T2DM patients from healthy controls.\(^\text{97}\) Notably, the miRNAs signature sometimes is able to predict diabetes development in 70% of patients in a 10 year follow-up.

Conclusion

Exhaustive lists of miRNAs have been implicated in the metabolic syndrome and diabetes mellitus. Although the full repertoire of miRNAs involved in β-cell differentiation and functions remains to be elucidated, more defined number of microRNAs appear to affect the function or differentiation of the pancreatic β-cells. However, microRNAs in skeletal muscle, liver and adipose tissue constitute different and almost non-overlapping sets of microRNA. Collectively, the hunt for new regulatory miRNAs in different cell types is still open.

Acknowledgments

The authors would like to thank Dr. Louise Torp Dalggaard, Roskilde University, for the valuable comments and advice during the preparation of this paper.

Ethical Issues

Not applicable.

Conflict of Interest

Authors declare no conflict of interest in this study.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ABCG4 | ATP-binding cassette sub-family G member 4 |
| Ago | Argonault |
| BAT | Brown adipose tissue |
| GSIS | Glucose stimulated insulin secretion |
| HDL | High density lipoprotein |
| IR | Insulin resistance |
| miRNA | microRNA |
| PGC-1α | peroxisome proliferator-activated receptor gamma coactivator 1-alpha |
| RIP | Rat insulin promoter |
| RISC | RNA-induced silencing complex |
| SNARE | Soluble NSF-attachment protein receptor |
| T1D | Type 1 diabetes |
| T2D | Type 2 diabetes |
| UTR | Untranslated region |
| VLDL | Very low density lipoprotein |
| WAT | White adipose tissue |

References

1. Bianchi M, Renzini A, Adamo S, Moresi V. Coordinated Actions of MicroRNAs with other Epigenetic Factors Regulate Skeletal Muscle Development and Adaptation. *Int J Mol Sci* 2017;18(4):840. doi: 10.3390/ijms18040840
2. Ørøm UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5′UTR of ribosomal protein mRNAs and
enhances their translation. Mol Cell 2008;30(4):460-71. doi: 10.1016/j.molcel.2008.05.001
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843-54. doi: 10.1016/0092-8674(93)90529-y
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75(5):855-62. doi: 10.1016/0092-8674(93)90530-4
5. Lee RC, Ambros V. An extensive class of small RNAs in caenorhabditis elegans. Science 2001;294(5543):862-4. doi: 10.1126/science.1065329
6. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97.
7. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat Rev Genet 2011;12(2):99-110. doi: 10.1038/nrg2936
8. Ul Hussain M. Micro-RNAs (miRNAs): Genomic organisation, biogenesis and mode of action. Cell Tissue Res 2012;349(2):405-13. doi: 10.1007/s00441-012-1438-0
9. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015;87:3-14. doi: 10.1016/j.addr.2015.05.001
10. Horak M, Novak J, Bienertova-Vasku J. Muscle-specific microRNAs in skeletal muscle development. Dev Biol 2016;410(1):1-13. doi: 10.1016/j.ydbio.2015.12.013
11. Bortolin-Cavaillé ML, Dance M, Weber M, Cavaillé J. C19MC microRNAs are processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids Res 2009;37(10):3464-73. doi: 10.1093/nar/gkp205
12. Zheng Q, Yang HJ, Yuan YA. Autoantigen La mediates the nuclear export of pre-microRNAs to promote microRNA maturation by Drosha. Mol Cell 2010;39(3):373-84. doi: 10.1016/j.molcel.2010.07.011
13. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosophila. Mol Cell 2010;39(3):373-84. doi: 10.1016/j.molcel.2010.07.011
14. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17(24):3011-6. doi: 10.1101/gad.1158803
15. Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. Elegans developmental timing. Cell 2001;106(1):23-34. doi: 10.1016/s0092-8674(01)00431-7
16. Zhang Y, Sun X, Icli B, Feinberg MW. Emerging roles for microRNAs in diabetic microvascular disease: Novel targets for therapy. Endocr Rev 2017;2017(1):1-22.
17. Sohel MH. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achiev the Life Sci 2016;10(2):175-86. doi: 10.1016/j.als.2016.11.007
18. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harde BF, German MS. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 2007;56(12):2938-45. doi: 10.2337/db07-0175
19. Mandelbaum AD, Melkman-Zehavi T, Oren R, Kredo-Russo S, Nir T, Dor Y, et al. Dysregulation of Dicer1 in beta cells impairs islet architecture and glucose metabolism. Exp Diabetes Res 2012;2012:470302. doi: 10.1155/2012/470302
20. Kalis M, Bolmeson C, Esguerra JL, Gupta S, Edlund A, Tormo-Badia N, et al. Beta-cell specific deletion of Dicer1 leads to defective insulin secretion and diabetes mellitus. Plos One 2011;6(12):e29166. doi: 10.1371/journal.pone.0029166
21. Martinez-Sanchez A, Nguyen-Tu MS, Rutter GA. DICER Inactivation Identifies Pancreatic beta-Cell "Disallowed" Genes Targeted by MicroRNAs. Mol Endocrinol 2015;29(7):1067-79. doi: 10.1210/me.2015-1059
22. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432(7014):226-30. doi: 10.1038/nature03076
23. Wei R, Yang J, Liu GQ, Gao MJ, Hou WF, Zhang L, et al. Dynamic expression of microRNAs during the differentiation of human embryonic stem cells into insulin-producing cells. Gene 2013;518(2):246-55. doi: 10.1016/j.gene.2013.01.038
24. Jafarian A, Taghikani M, Abroun S, Allahverdi A, Lamei M, Lakpour N, et al. The Generation of Insulin Producing Cells from Human Mesenchymal Stem Cells by MiR-375 and Anti-MiR-9. Plos One 2015;10(6):e0128650. doi: 10.1371/journal.pone.0128650
25. Nathan G, Kredo-Russo S, Geiger T, Lenz A, Kaspi H, Hornstein E, et al. MiR-375 promotes redifferentiation of adult human β cells expanded in vitro. PLoS One 2015;10(4):e0122108. doi: 10.1371/journal.pone.0122108
26. Tattikota SG, Rathjen T, McAnulty SJ, Wessels HH, Akerman I, van de Bunt M, et al. Argonaute2 mediates compensatory expansion of the pancreatic β cell. Cell Metab 2014;19(1):122-34. doi: 10.1016/j.cmet.2013.11.015
27. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharffmann R, et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic β-cell lines. J Biol Chem 2007;282(27):19575-88. doi: 10.1074/jbc.M611841200
28. Joglekar MV, Parekh VS, Mehta S, Bhonde RR, Hardikar AA. MicroRNA profiling of developing and regenerating pancreas reveal post-transcriptional regulation of neurogenin3. Dev Biol 2007;311(2):603-12. doi: 10.1016/j.ydbio.2007.09.008

29. Eliasson L, Eguerra JLS, Wendt A. Lessons from basic pancreatic beta cell research in type-2 diabetes and vascular complications. Diabetol Int 2017;8(2):139-52.

30. Åmmälä C, Ashcroft FM, Rorsman P. Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature 1993;363(6427):356-8. doi: 10.1038/363356a0

31. Renström E, Eliasson L, Rorsman P. Protein kinase A-dependent and -independent stimulation of exocytosis by cAMP in mouse pancreatic B-cells. J Physiol 1997;502(1):105-18. doi: 10.1111/j.1469-7793.1997.105bl.x

32. Keller DM, Clark EA, Goodman RH. Regulation of microRNA-375 by cAMP in pancreatic β-cells. Mol Endocrinol 2012;26(6):989-99. doi: 10.1210/me.2011-1205

33. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. cAMP-mediated regulation of neurogenin3. Dev Biol 2000;238(2):403-13. doi: 10.1006/dbio.2000.1029

34. Ramachandran D, Roy U, Garg S, Ghosh S, Pathak S, Kolthur-Seetharam U. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic β-islets. FEBS J 2011;278(7):1167-74. doi: 10.1111/j.1742-4658.2011.08042.x

35. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, Regazzi R. MicroRNA-9 controls the expression of Granulpholin/Sip4 and the secretory response of insulin-producing cells. J Biol Chem 2006;281(37):26932-42. doi: 10.1074/jbc.M601225200

36. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008;389(3):305-12. doi: 10.1515/BC.2008.026

37. Hou X, Wu W, Yin B, Liu X, Ren F. MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion. Obesity (Silver Spring) 2016;24(11):2368-76. doi: 10.1002/oby.21655

38. Matsumoto M, Miki T, Shibasaki T, Kawaguchi M, Shinozaki H, Nio J, et al. Noc2 is essential in normal regulation of exocytosis in endocrine and exocrine cells. Proc Natl Acad Sci U S A 2004;101(22):8313-8. doi: 10.1073/pnas.0306790101

39. Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, Meda P, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic β-cells. Diabetes 2010;59(4):978-86. doi: 10.2337/db09-0881

40. Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, Widmann C, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic β-cell dysfunction. Diabetes 2008;57(10):2728-36. doi: 10.2337/db07-1252

41. Bagge A, Dahmcke CM, Dalgaard LT. Syntaxin-1a is a direct target of miR-29a in insulin-producing β-cells. Horm Metab Res 2013;45(6):463-6. doi: 10.1515/hmre-2013-0485

42. Andrali SS, Sampley ML, Vanderford NL, Özcan S. Glucose regulation of insulin gene expression in pancreatic β-cells. Biochem J 2008;415(1):1-10. doi: 10.1042/BJ20081029

43. Xu G, Chen J, Jing G, Shalev A. Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med 2013;19(9):1141-6. doi: 10.1038/nm.3287

44. Tang X, Muniappan L, Tang G, Özcan S. Identification of glucose-regulated miRNAs from pancreatic β cells reveals a role for mir-30d in insulin transcription. Rna 2009;15(2):287-93. doi: 10.1261/rna.1211209

45. Zhao X, Mohan R, Özcan S, Tang X. MicroRNA-30d induces insulin transcription factor MafA and insulin production by targeting mitogen-activated protein kinase 4 kinase 4 (MAP4K4) in pancreatic β-cells. J Biol Chem 2012;287(37):31155-64. doi: 10.1074/jbc.M112.362632

46. El Ouamari A, Barouk N, Martens GA, Lebrun P, Pipeleers D, Van Obberghen E. miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic β-cells. Diabetes 2008;57(10):2708-17. doi: 10.2337/db07-1614

47. Plaisance V, Waebir G, Regazzi R, Abderrahmani A. Role of microRNAs in islet beta-cell compensation and failure during diabetes. J Diabetes Res 2014;2014. doi: 10.1155/2014/618652

48. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A, et al. β-cell replication is the primary mechanism subserving the postnatal expansion of β-cell mass in humans. Diabetes 2008;57(6):1584-94. doi: 10.2337/db07-1369

49. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat 2007;20(8):933-42. doi: 10.1002/ca.20543

50. Eliasson L. The small RNA miR-375 - a pancreatic islet abundant miRNA with multiple roles in endocrine beta cell function. Mol Cell Endocrinol 2017;456:95-101. doi: 10.1016/j.mce.2017.02.043

51. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of...
miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 2007;5(8):e203. doi: 10.1371/journal.pbio.0050203
52. Poy MN, Haussler J, Trajkovski M, Braun M, Collins S, Rorsman P, et al. miR-375 maintains normal pancreatic α- and β-cell mass. Proc Natl Acad Sci U S A 2009;106(14):5813-8. doi: 10.1073/pnas.0810550106
53. Correa-Medina M, Bravo-Egana V, Rosero S, Ricordi C, Edlund H, Diez J, et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr Patterns 2009;9(4):193-9. doi: 10.1016/j.gep.2008.12.003
54. Rosero S, Bravo-Egana V, Jiang Z, Khuri S, Tsinoremas N, Klein D, et al. MicroRNA signature of the human developing pancreas. BMC Genomics 2010;11:509. doi: 10.1186/1471-2164-11-509
55. Joglekar MV, Joglekar VM, Hardiak AA. Expression of islet-specific microRNAs during human pancreatic development. Gene Expr Patterns 2009;9(2):109-13. doi: 10.1016/j.gep.2008.10.001
56. Wang Y, Liu J, Liu C, Naji A, Stoffers DA. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic β-cells. Diabetes 2013;62(3):887-95. doi: 10.23737/db12-0451
57. Butler AE, Cao-Minh L, Galasso R, Rizza RA, Corradin A, Cobelli C, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 2010;53(10):2167-76. doi: 10.1007/s00125-010-1809-6
58. Belgardt BF, Ahmed K, Spranger M, Latreille M, Denzl R, Kondratiiuk N, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med 2015;21(6):619-27. doi: 10.1038/nm.3862
59. Sims EK, Lakhter AJ, Anderson-Baucum E, Kono T, Tong X, Evans-Molina C. MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. Diabetologia 2017;60(6):1057-65. doi: 10.1007/s00125-017-4237-z
60. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009;32(Suppl 2):S157-63. doi: 10.2337/dc09-S302
61. Williams CB, Gurd BJ. Skeletal muscle SIRT1 and the genetics of metabolic health: Therapeutic activation by pharmaceuticals and exercise. Appl Clin Genet 2012;5:81-91. doi: 10.2147/TACG.S31276
62. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004;5(3):R13. doi: 10.1186/gb-2004-5-3-r13
63. Small EM, O’Rourke JR, Moresi V, Sutherland LB, McAnally J, Gerard RD, et al. Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486. Proc Natl Acad Sci U S A 2010;107(9):4218-23. doi: 10.1073/pnas.1000300107
64. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316(5824):575-9. doi: 10.1126/science.1139089
65. Dahlmans D, Houzelle A, Andreux P, Jorgensen JA, Wang X, de Windt LJ, et al. An unbiased silencing screen in muscle cells identifies miR-320a, miR-150, miR-196b, and miR-34c as regulators of skeletal muscle mitochondrial metabolism. Mol Metab 2017;6(11):1429-42. doi: 10.1016/j.molmet.2017.08.007
66. Voisin S, Eynon N, Yan X, Bishop DJ. Exercise training and DNA methylation in humans. Acta Physiol (Oxf) 2015;213(1):39-59. doi: 10.1111/apha.12414
67. McLean CS, Mielke C, Cordova JM, Langlais PR, Bowen B, Miranda D, et al. Gene and microRNA expression responses to exercise; relationship with insulin sensitivity. PLoS One 2015;10(5):e0127089. doi: 10.1371/journal.pone.0127089
68. Russell AP, Lamon S, Boon H, Wada S, Guller I, Brown EL, et al. Regulation of miRNAs in human skeletal muscle following acute endurance exercise and short-term endurance training. J Physiol 2013;591(18):4637-53. doi: 10.1113/jphysiol.2013.255695
69. Nielsen S, Scheele C, Yfantí C, Åkerström T, Nielsen AR, Pedersen BK, et al. Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. J Physiol 2010;588(Pr 20):4029-37. doi: 10.1113/jphysiol.2010.189860
70. Safdar A, Abadi A, Akhtar M, Hettinga BP, Tarnopolsky MA, miRNA in the regulation of skeletal muscle adaptation to acute endurance exercise in C57BL/6J male mice. PloS One 2009;4(5):e5610. doi: 10.1371/journal.pone.0005610
71. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444(7121):847-53. doi: 10.1038/nature05483
72. Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PloS One 2010;5(2):e9022. doi: 10.1371/journal.pone.0009022
73. Chiang TY, Wu HL, Chen CC, Gamboa GM, Layman LC, Diamond MP, et al. MicroRNA-223 expression is upregulated in insulin resistant human adipose tissue. J Diabetes Res 2015;2015:943659. doi: 10.1155/2015/943659
MicroRNAs, glucose tolerance and diabetes

74. Xu G, Ji C, Song G, Zhao C, Shi C, Song L, et al. miR-26b modulates insulin sensitivity in adipocytes by interrupting the PTEN/PI3K/AKT pathway. Int J Obes (Lond) 2015;39(10):1523-30. doi: 10.1038/ijo.2015.95

75. Ling HY, Ou HS, Feng SD, Zhang XY, Tuo QH, Chen LX, et al. CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009;36(9):e32-9. doi: 10.1111/j.1440-1681.2009.05207.x

76. Guglielmi V, D’Adamo M, Menghini R, Cardellini M, Gentilesci P, Federici M, et al. MicroRNA 21 is up-regulated in adipose tissue of obese diabetic subjects. Nutr Healthy Aging 2017;4(2):141-5. doi: 10.3233/NHA-160020

77. Chen YH, Heneidi S, Lee JM, Layman LC, Stepp DW, Gamboa GM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes 2013;62(7):2278-86. doi: 10.2337/db12-0963

78. Trajkovski M, Hauser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474(7353):649-53. doi: 10.1038/nature10112

79. Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011;13(4):434-46. doi: 10.1038/ncb2211

80. Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia 2013;56(9):1971-9. doi: 10.1007/s00125-013-2950-9

81. Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, et al. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 2017;171(2):372-84.e12. doi: 10.1016/j.cell.2017.08.035

82. Lee P, Greenfield JR, Ho KK, Fulham MJ. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2010;299(4):E601-6. doi: 10.1152/ajpendo.00298.2010

83. Arias N, Aguirre L, Fernández-Quintela A, González M, Lasa A, Miranda J, et al. MicroRNAs involved in the browning process of adipocytes. J Physiol Biochem 2016;72(3):509-21. doi: 10.1007/s13105-015-0459-z

84. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-125 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3(2):87-98. doi: 10.1016/j.cmet.2006.01.005

85. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012;122(8):2884-97. doi: 10.1172/JCI63455

86. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 2014;111(40):14518-23. doi: 10.1073/pnas.1215767111

87. Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreo U, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011;108(22):9232-7. doi: 10.1073/pnas.1102281108

88. Rayner JK, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328(5985):1570-3. doi: 10.1126/science.1189862

89. Kurtz CL, Fannin EE, Toth CL, Pearson DS, Vickers KC, Sethupathy P. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep 2015;5:12911. doi: 10.1038/srep12911

90. Zhou B, Li C, Qi W, Zhang Y, Zhang F, Wu JX, et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012;55(7):2032-43. doi: 10.1007/s00125-012-2539-8

91. Vienberg S, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. Acta physiol (Oxf) 2017;219(2):346-61. doi: 10.1111/apha.12681

92. Guay C, Jacovetti C, Nesca V, Motterle A, Tugay K, Regazzi R. Emerging roles of non-coding RNAs in pancreatic β-cell function and dysfunction. Diabetes Obes Metab 2012;14(Suppl 3):12-21. doi: 10.1111/j.1463-2126.2012.01654.x

93. Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF, et al. MicroRNA 144 impairs pancreatic β-cell function by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. Plos One 2011;6(8):e22839. doi: 10.1371/journal.pone.0022839

94. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in prediabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol 2011;48(1):61-9. doi: 10.1007/s00592-010-0226-0

95. Pescador N, Pérez-Barba M, Ibarra JM, Corbatón A, Martínez-Larrad MT, Serrano-Ríos M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. Plos One 2013;8(10):e77251. doi: 10.1371/journal.pone.0077251

96. Zampetaki A, Kiechl S, Drozdog I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling
reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res* 2010;107(6):810-7. doi: 10.1161/CIRCRESAHA.110.226357

97. Ghai V, Wang K. Recent progress toward the use of circulating microRNAs as clinical biomarkers. *Arch Toxicol* 2016;90(12):2959-78. doi: 10.1007/s00204-016-1828-2

98. Bagge A, Clausen TR, Larsen S, Ladefoged M, Rosenstierne MW, Larsen L, et al. MicroRNA-29a is up-regulated in beta-cells by glucose and decreases glucose-stimulated insulin secretion. *Biochem Biophys Res Commun* 2012;426(2):266-72. doi: 10.1016/j.bbrc.2012.08.082

99. Nieto M, Hevia P, Garcia E, Klein D, Alvarez-Cubela S, Bravo-Egana V, et al. Antisense miR-7 impairs insulin expression in developing pancreas and in cultured pancreatic buds. *Cell Transplant* 2012;21(8):1761-74. doi: 10.3727/096368911X612521

100. Güller I, Russell AP. MicroRNAs in skeletal muscle: Their role and regulation in development, disease and function. *J Physiol* 2010;588(Pt 21):4075-87. doi: 10.1113/jphysiol.2010.194175

101. Koning M, Werker PM, van Luyn MJ, Krenning G, Harmesen MC. A global downregulation of microRNAs occurs in human quiescent satellite cells during myogenesis. *Differentiation* 2012;84(4):314-21. doi: 10.1016/j.diff.2012.08.002

102. Yang WM, Jeong HJ, Park SY, Lee W. Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes. *FEBS Lett* 2014;588(13):2170-6. doi: 10.1016/j.febslet.2014.05.011

103. McCarthy JJ. MicroRNA-206: The skeletal muscle-specific myomiR. *Biochim Biophys Acta* 2008;1779(11):682-91. doi: 10.1016/j.bbagrm.2008.03.001

104. Zhang Y, Yang L, Gao YF, Fan ZM, Cai XY, Liu MY, et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. *Mol Cell Endocrinol* 2013;381(1-2):230-40. doi: 10.1016/j.mce.2013.08.004

105. Ferland-Mccollough D, Ozanne SE, Siddle K, Willis AE, BusHELL M. The involvement of microRNAs in type 2 diabetes. *Biochem Soc Trans* 2010;38(6):1565-70. doi: 10.1042/BST0381565

106. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. *FEBS J* 2009;276(8):2348-58.

107. Esau C, Kang X, Peralta E, Hanson E, Marcussen EG, Ravichandran LV, et al. MicroRNA-143 regulates adipocyte differentiation. *J Biol Chem* 2004;279(50):52361-5. doi: 10.1074/jbc.C400438200

108. Aranda JF, Madrigal-Matute J, Rotllan N, Fernandez-Hernando C. MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases. *Free Radic Biol Med* 2013;64:31-9. doi: 10.1016/j.freeradbiomed.2013.07.014

109. Kornfeld JW, Baitzel C, Könner AC, Nicholls HT, Vogt MC, Herrmanns K, et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. *Nature* 2013;494(7435):111-5. doi: 10.1038/nature11793